Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a report published on Friday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Down 3.5 %

Shares of TRVN stock opened at $1.93 on Friday. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $19.23. The stock has a market cap of $1.41 million, a P/E ratio of -0.03 and a beta of 1.02. The business has a fifty day simple moving average of $3.89 and a 200-day simple moving average of $6.73.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($9.25) by $9.02. The firm had revenue of $0.33 million during the quarter. On average, sell-side analysts anticipate that Trevena will post -32.25 earnings per share for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.